At its July meeting, the Pharmaceutical Benefits Advisory Committee delivered a mixed result on one company's request for relief on a risk share agreement and is planning further consideration on the future of a PBS-listed COVID-19 therapy.
PBAC July outcomes a win for CF patients and AZ cancer therapies
August 21, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech